Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

A Phase 1a/b Dose Escalation Study of the MYC Repressor Apto-253 in Patients with Relapsed or Refractory AML or High-Risk MDS

Maro Ohanian, Martha L. Arellano, Moshe Y. Levy, Kristen O'Dwyer, Hani Babiker, Daruka Mahadevan, Hongying Zhang, Nasrin Rastgoo, Yuying Jin, Jotin Marango, Stephen B Howell, William G Rice, Rafael Bejar

Blood (2021) 138 (Supplement 1): 3411.

https://doi.org/10.1182/blood-2021-150049

Published: 2021

Journal Articles

A Phase 1a/b Dose Escalation Study of the Mutation Agnostic FLT3/BTK Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Aaron D Goldberg, Maro Ohanian, Paul Koller, Jessica K. Altman, Mohamad Cherry, Benjamin Tomlinson, Namrata Chandhok, Hongying Zhang, Nasrin Rastgoo, Khalid Benbatoul, Yuying Jin, Genia Su, Jotin Marango, Stephen B Howell, William G Rice, Rafael Bejar

Blood (2021) 138 (Supplement 1): 1272.

https://doi.org/10.1182/blood-2021-149333

Published: 2021

Journal Articles

A Phase 1a/b Dose Escalation Study of the Mutation Agnostic BTK/FLT3 Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory B-Cell Malignancies

Blood (2021) 138 (Supplement 1): 1355.

https://doi.org/10.1182/blood-2021-148827

Published: 2021

Journal Articles

A Phase 1 a/b Dose Escalation Study of the Mutation Agnostic BTK/FLT3 Inhibitor CG-806 in Patients with Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

Rafael Bejar, MD PhD, Hongying Zhang, MDPhD, Nasrin Rastgoo, PhD, Khalid Benbatoul, BS, Yuying Jin, PhD, Matthew Thayer, BS., Susan Sheng, PhD, Gregory k Chow, BA, MBA, Victor Montalvo-Lugo, Jotin Marango, MD, Stephen B Howell, MD, William G Rice, PhD

Blood (2020) 136 (Supplement 1): 35.

https://doi.org/10.1182/blood-2020-141495

Published: 2020

Journal Articles

A Phase 1a/b Dose Escalation Study of the MYC Repressor Apto-253 in Patients with Relapsed or Refractory AML or High-Risk MDS

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-141409

Published: 2020

Journal Articles

Targeting CD47 and TNFAIP8 By Mir-155 Overcomes Drug Resistance and Inhibits Tumor Growth through Induction of Phagocytosis and Apoptosis in Multiple Myeloma

Nasrin Rastgoo, PhD, Jahangir Abdi, PhD, Maryam Pourabdollah, MD, Hong Chang, MD

Blood (2018) 132 (Supplement 1): 1923.

https://doi.org/10.1182/blood-2018-99-113057

Published: 2018

Journal Articles

Marcks Inhibition By a Peptide Inhibitor, MPS, Cooperates with Bortezomib to Effectively Eliminate Drug Resistance in Multiple Myeloma

Lun Zhang, Nasrin Rastgoo, PhD, Maryam Pourabdollah, MD, Eldad Zacksenhaus, PhD, Yan Chen, MD PhD, Guoan Chen, MD, Hong Chang, MD

Blood (2018) 132 (Supplement 1): 1936.

https://doi.org/10.1182/blood-2018-99-113026

Published: 2018

Journal Articles

Targeting of Marcks By MiR-34a Overcomes Drug Resistance in Multiple Myeloma

Nasrin Rastgoo, PhD, Yan Chen, MD PhD, Jahangir Abdi, PhD, Minjing Wang, Chen Guoan, MD, Hong Chang, MD

Blood (2017) 130 (Supplement 1): 4377.

https://doi.org/10.1182/blood.V130.Suppl_1.4377.4377

Published: 2017

Journal Articles

Inhibition of the Epigenetic Modifier EZH2 By Mir-138 Upregulates Tumor Suppressor Gene Rbpms and Contributes to Drug Susceptibility in Preclinical Model of Multiple Myeloma

Nasrin Rastgoo, PhD, Maryam Pourabdollah, MD, Jahangir Abdi, PhD BSc, MSc, Hong Chang, MD

Blood (2017) 130 (Supplement 1): 269.

https://doi.org/10.1182/blood.V130.Suppl_1.269.269

Published: 2017

Journal Articles

Restoration of Mir-138 Expression By Epigenetic Modulation Overcomes Drug Resistance in Multiple Myeloma Cells

Nasrin Rastgoo, PhD, Jahangir Abdi, PhD, Lun Zhang, PhD, Minjing Wang, Hong Chang, MD PhD

Blood (2016) 128 (22): 2060.

https://doi.org/10.1182/blood.V128.22.2060.2060

Published: 2016

Journal Articles

Marcks Peptide Inhibitor Displays Synergistic Cytotoxicity with Bortezomib in Drug Resistant Multiple Myeloma Cells but Enhances Autophagic Effect

Lun Zhang, PhD, Jahangir Abdi, PhD, Minjing Wang, Nasrin Rastgoo, PhD, Hong Chang, MD PhD

Blood (2016) 128 (22): 2061.

https://doi.org/10.1182/blood.V128.22.2061.2061

Published: 2016

NARROW

A Phase 1a/b Dose Escalation Study of the MYC Repressor Apto-253 in Patients with Relapsed or Refractory AML or High-Risk MDS

A Phase 1a/b Dose Escalation Study of the Mutation Agnostic FLT3/BTK Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

A Phase 1a/b Dose Escalation Study of the Mutation Agnostic BTK/FLT3 Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory B-Cell Malignancies

A Phase 1 a/b Dose Escalation Study of the Mutation Agnostic BTK/FLT3 Inhibitor CG-806 in Patients with Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

A Phase 1a/b Dose Escalation Study of the MYC Repressor Apto-253 in Patients with Relapsed or Refractory AML or High-Risk MDS

Targeting CD47 and TNFAIP8 By Mir-155 Overcomes Drug Resistance and Inhibits Tumor Growth through Induction of Phagocytosis and Apoptosis in Multiple Myeloma

Marcks Inhibition By a Peptide Inhibitor, MPS, Cooperates with Bortezomib to Effectively Eliminate Drug Resistance in Multiple Myeloma

Targeting of Marcks By MiR-34a Overcomes Drug Resistance in Multiple Myeloma

Inhibition of the Epigenetic Modifier EZH2 By Mir-138 Upregulates Tumor Suppressor Gene Rbpms and Contributes to Drug Susceptibility in Preclinical Model of Multiple Myeloma

Restoration of Mir-138 Expression By Epigenetic Modulation Overcomes Drug Resistance in Multiple Myeloma Cells

Marcks Peptide Inhibitor Displays Synergistic Cytotoxicity with Bortezomib in Drug Resistant Multiple Myeloma Cells but Enhances Autophagic Effect

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only